DUSA Pharmaceuticals Surpasses One Million in Cumulative Levulan(R)
Kerastick(R) Sales Units
WILMINGTON, Mass., Oct. 28 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals,
Inc.® (Nasdaq GM: DUSA), a specialty pharmaceutical company focused on
dermatology, announced today that global sales volumes of the Levulan®
Kerastick®, an integral part of the Levulan® Photodynamic Therapy (PDT)
technology platform, surpassed one million units.
"The achievement of this milestone signifies that dermatologists in the U.S.
and abroad continue to embrace Levulan PDT for Grade 1 and 2 actinic keratoses
(AKs) of the face and scalp and the beneficial outcomes it offers their
patients," said Bob Doman, DUSA's President and Chief Executive Officer.
"We believe that Levulan PDT is one of the fastest growing office based
procedures in dermatology today, having achieved a 39% compounded annual
growth rate in worldwide Kerastick revenues over the past four years,"
continued Doman.
"PDT is an important, versatile technology that should be integrated more
frequently in clinical dermatology practice," said Jill Waibel, M.D., a
dermatologist in private practice at Palm Beach Esthetic Dermatology & Laser
Center, West Palm Beach, Florida.
"We are excited to have reached the one million Kerastick sales milestone, and
believe that significant growth potential exists for Levulan PDT in the
treatment of AKs and other potential indications," Doman concluded.
DUSA continues to explore other potential indications for the utilization of
Levulan PDT for the treatment of various skin conditions and has initiated a
pilot study on Levulan PDT for the treatment of AKs and the prevention of new
non-melanoma skin cancer in chronically immunosuppressed solid organ
transplant recipients.
About DUSA Pharmaceuticals
DUSA Pharmaceuticals, Inc. ® is an integrated dermatology pharmaceutical
company focused primarily on the development and marketing of its Levulan®
Photodynamic Therapy technology platform, and complementary dermatology
products. Levulan PDT is currently approved for the treatment of Grade 1 and
2 actinic keratoses of the face and scalp. DUSA also markets other
dermatology products, including ClindaReach®. DUSA is researching Levulan PDT
for the treatment of AKs and the prevention of new non-melanoma skin cancer in
chronically immunosuppressed solid organ transplant recipients. DUSA is based
in Wilmington, Mass. Please visit our Web site at www.dusapharma.com.
Forward Looking Statements
Except for historical information, this news release contains certain
forward-looking statements that represent our current expectations and beliefs
concerning future events, and involve certain known and unknown risk and
uncertainties. These forward-looking statements relate to belief concerning
the speed of Levulan growth and its potential for additional growth and
additional indications. These forward-looking statements are further
qualified by important factors that could cause actual results to differ
materially from future results, performance or achievements expressed or
implied by those in the forward-looking statements made in this release.
These factors include, without limitation, actions by health regulatory
authorities, sufficiency of funds, the regulatory approval process, results of
clinical trials, reliance on third party manufacturers, our patent portfolio,
and other risks and uncertainties identified in DUSA's Form 10-K for the year
ended December 31, 2008, and other SEC filings from time to time.
SOURCE DUSA Pharmaceuticals, Inc.
Investor Relations: Chad Rubin of The Trout Group LLC, +1-646-378-2947; or
Media: Dayna Hochstein of Spectrum, +1-202-955-6222 Ext. 2524, both for DUSA
Pharmaceuticals, Inc.
